Thrombocytopenia: First Symptom in a Patient with Dyskeratosis Congenita

PEDIATRICS ◽  
1981 ◽  
Vol 67 (6) ◽  
pp. 898-903
Author(s):  
Kris De Boeck ◽  
H. Degreef ◽  
R. Verwilghen ◽  
L. Corbeel ◽  
Maria Casteels-Van Daele

A case of dyskeratosis congenita is reported. This rare hereditary disease usually has the following progression: ectodermal dystrophy (reticular skin pigmentation, nail dystrophy, leukokeratosis of mucosal membranes), appearing in the first decade, followed in about 50% of these patients by a hematopoietic disorder resembling Fanconi's anemia, usually developing in the second or third decade. Carcinomas may occur in leukokeratotic areas in the third, fourth, or fifth decade. This patient's clinical course is interesting because the thrombocytopenia developed as an isolated symptom at the age of 5 years and preceded the skin anomalies by three years. The diagnosis of dyskeratosis congenita was made only after an evolution of five years. The diagnosis of dyskeratosis congenita—although it is a rare disease—should be considered in every child first seen with aplastic anemia or thrombocytopenia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1057-1057
Author(s):  
Neelam Giri ◽  
Dalia Batista ◽  
Constantine Stratakis ◽  
Ekaterini T. Tsilou ◽  
Hung J. Kim ◽  
...  

Abstract Fanconi’s anemia (FA) is an inherited DNA repair disorder with very high risks of aplastic anemia (AA), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and squamous cell carcinomas (SCC). Patients with FA often have physical anomalies, and may develop endocrinopathies; these phenotypic features may be associated with adverse outcomes. While most of these abnormalities have been previously-reported, only prospective follow-up of a meticulously-characterized cohort can accurately quantify the prevalence and natural history of each, and determine whether specific abnormalities are strongly predictive of adverse outcomes; such information will be invaluable for evidence-based management of FA patients. To begin our formal investigation of these associations, we reviewed the medical records of 42 study participants with FA, and began prospective evaluation of a subset of 20 patients who underwent multidisciplinary evaluation at the NIH Clinical Center (FA Clinical Center Cohort - CC). The remaining 22 patients were in the FA Field Cohort (FC). We studied 17 males and 25 females. The CC and FC subjects were similar except that the former were older at the time of study (median 21.5 vs 14.3 yrs in the FC, p=0.01) and had later onset of aplastic anemia (11.8 vs 7.2 yrs, p=0.03). 36/42 (86%) had at least one FA-related congenital anomaly. 11 patients were FANCA, 9 FANCC, and 1 each FANCD1/BRCA2, FANCF, and FANCJ. 34/42 (81%) had aplastic anemia; 10 had mild to moderate and 24 had severe AA. 13/33 (38 %) had clonal cytogenetic bone marrow abnormalities, some for >3 years. 8/42 (19%) developed MDS, one of whom evolved to AML. 12 (29%) underwent BMT, 9 of whom are alive (median 4 yrs, range 9 mo-21 yrs). 3 patients were hematopoietic somatic mosaics, in whom the diagnosis of FA was confirmed by detection of chromosome breakage in skin fibroblasts; all 3 had mutations in FANCA. 23/36 (64%) had hearing loss, 4 of whom had surgery for middle ear bony abnormalities. 28/32 had microcornea, 20 microophthalmia, 21 myopia, and 4 had ptosis. 32/36 (89%) had multiple café-au-lait spots and hyper/hypopigmented areas, and 2 had Sweet’s syndrome with MDS. 9/19 (47%) had leukoplakia; 1 biopsy was positive for SCC. 29/42 (69%) had one or more endocrinopathy, including short stature, hypothyroidism, growth hormone deficiency, glucose intolerance, diabetes, dyslipidemia and metabolic syndrome. 5 patients had mid-line structural anomalies of the brain, and 1 each had a lipoma and a brain tumor. 2 patients had nonalcoholic steatohepatitis, 1 had transfusional hemosiderosis and 1 had a liver adenoma. 7/8 adult females had infertility and premature ovarian failure; 5 males had hypogenitalia. 7/7 females and 2/4 males older than 18 yrs had osteopenia or osteoporosis. 9 patients had 12 prevalent cancers at a median age of 29 yrs (range 5–44), including 5 head and neck, 4 vulvar, and 1 each nasopharyngeal, skin and brain tumor. One of the head and neck SCC occurred 13 years after BMT. Prospective screening at the NIH identified recurrent head and neck SCC in 3 patients. We conclude that FA patients need to be examined frequently in comprehensive subspecialty clinics to identify and treat significant co-morbidities, including hematologic, endocrine, and neoplastic disorders. Analysis of genotype/phenotype/cancer correlations in FA will require thorough evaluations of the type outlined here, involving larger numbers of patients; accrual to, and follow-up of, our FA cohort continues.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3751-3751
Author(s):  
Guillermo I. Drelichman ◽  
Nora F. Basack ◽  
Alejandra Maro ◽  
Graciela Schwalb ◽  
Daniel H. Freigeiro ◽  
...  

Abstract Inherited bone marrow failure syndromes (IBMFS) present chronic bone marrow failures, a familial incidence and high risk of malignancy. Objective: we describe our experience with patients with IBMFS. Since 02/73 to 02/05, 60 patients (pts) with IBMSF were diagnosed. Fanconi’s Anemia Blackfand-Diamond TAR-Shwachman-Diamond-Dyskeratosis Congenita Amegakaryocytic Thrombocytopenia.- Kostmann’s S. Familial AA-Pearson’s S N Pts 26 17 6 – 2 – 2 2 – 2 2 – 1 Median age at diagnosis 7.1 y 3 m 3m – 4 m – 6.4 y 2 m – 1.8 m 4 y – 3 y First hematologic sign Pancytopenia Anemia Thrombocytop. – Neutrop. – Pancytop. Thrombocytop. – Neutrop. Pancytop. – Anemia Bone Marrow Aplastic Erythroid Aplasia Megakar. Aplasia – Myeloid arrest– Aplastic Megakar. Aplasia– Myeloid arrest Aplastic – Vacuolated myeloid Physical Abnorm.(%) 88 47 100 – 50– 100 50 – 0 0 – 0 Aplastic Anemia (%) 100 0 0 – 0 – 100 50 – 0 100 – 100 Leukemia / MDS (%) 11.5 0 0 – 0 – 0 0 – 0 0 – 0 Mortality(%) 62 0 17 – 50 – 0 50 – 50 50 – 0 Conclusion: 68 % pts. presented with associated physical abnormalities, 53 % began the symptoms with bone marrow aplasia. With a median follow up: 16. 3 years (r: 1y – 32 y), 39 (65%) pts are alive (9 pts. post bone marrow transplantation) and 3 pts with Fanconi’s Anemia developed refractory Acute Myeloblastic Leukemia.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 836-836
Author(s):  
Hong-Yan Du ◽  
Elena Pumbo ◽  
Akiko Shimamura ◽  
Adrianna Vlachos ◽  
Jeffrey M. Lipton ◽  
...  

Abstract Dyskeratosis congenita (DC) is a rare inherited bone marrow failure (BMF) syndrome. The classical features of DC include nail dystrophy, abnormal skin pigmentation, and mucosal leukoplakia. The diagnosis of DC can be difficult. Originally, the diagnosis was based on the presence of the classical mucocutaneous features. However, the identification of four genes responsible for DC (DKC1, TERC, TERT, and NOP10) showed that these mucocutaneous features are only present in a proportion of patients with DC. Additionally, screening for mutations in the affected genes is expensive and is negative in about 50% of patients with classical features of DC. The products of the genes mutated in DC are the components of the telomerase ribonucleoprotein complex, which is essential for telomere maintenance. Therefore it has been postulated that DC is a disease arising from excessive telomere shortening. Here we examined whether the measurement of telomeres could be used as a screening test to identify individuals with DC. For this purpose we examined telomere length in peripheral blood mononuclear cells from 169 patients who presented with bone marrow failure including 17 patients with DC, diagnosed by the presence of classical cutaneous features or the identification of mutations in DKC1, TERC or TERT, 28 patients with paroxysmal nocturnal hemoglobinuria, 25 patients with Diamond Blackfan anemia, 5 patients with Shwachman-Diamond syndrome, 8 patients with myelodysplastic syndrome, and 74 patients with aplastic anemia of unknown cause classified as idiopathic aplastic anemia. In addition we measured telomere length in 12 patients with idiopathic pulmonary fibrosis and in 45 individuals with a de novo deletion of chromosome 5p including the TERT gene. Their telomere lengths were compared with those of 202 age-matched healthy controls. Moreover, mutations were screened in the genes associated with DC. In cases where a mutation was identified, telomere length and mutations were also examined in all the family members. Our results show that all patients with DC and bone marrow failure have very short telomeres far below the first percentile of healthy controls. Not all mutation carriers, including some carriers of apparently dominant mutations, have very short telomeres. What is more, very short telomeres could be found in healthy individuals in these families, some of whom were not mutation carriers. These findings indicate that in patients with BMF the measurement of telomere length is a sensitive screening method for DC, whether very short telomeres in this setting are also specific for DC remains to be determined. However, in contrast to a previous study, we find that telomere length does not always identify mutation carriers in the families of DC.


2015 ◽  
Vol 04 (08) ◽  
pp. 271-275
Author(s):  
Abdihamid Mohamed Ali Rage ◽  
Abdirahman Osman Mohamud ◽  
Mohamed Abdulkadir Hassan Kadle

2021 ◽  
Vol 2021 (11) ◽  
Author(s):  
Firas Hussein ◽  
Zainab Omar

ABSTRACT Dyskeratosis congenita (DC) is an inherited disease characterized by the triad of abnormal skin pigmentation, nail dystrophy and mucosal leukoplakia. Non-cutaneous abnormalities (dental, gastrointestinal, genitourinary, neurological, ophthalmic, pulmonary and skeletal) have also been reported. Bone marrow failure (BMF) is the main cause of early mortality, with an additional predisposition to malignancy. DC results from an anomalous progressive shortening of telomeres resulting in DNA replication problems inducing replicative senescence. Men are more affected than women are and X-linked recessive, autosomal dominant and autosomal recessive forms of the disease are recognized. There are no targeted therapies for DC. Patients treated with androgens had a hematological response. We herein describe case of a 32-year-old man, presented with several characteristic systemic features of this condition, including the classic triad of lesions, dysplastic bone marrow, epiphora and liver cirrhosis with grade I esophageal varices. Therefore, a prophylactic propranolol was started in additional to danazol. Three-week later, the patient had subsequent increases in his platelet, red cell and white cell counts.


Blood ◽  
1972 ◽  
Vol 39 (4) ◽  
pp. 510-521 ◽  
Author(s):  
William Steier ◽  
G. Arthur Van Voolen ◽  
Victor J. Selmanowitz

Abstract Dyskeratosis congenita and Fanconi’s anemia share impressive features in common: primary refractory pancytopenia; bone marrow hyperplasia (curtailed phase) and megaloblastosis, eventuating in severe hypoplasia of the marrow; cutaneous melanotic dyschromia; lacrimal duct blockage and a host of other minor abnormalities, in addition to mental retardation and generalized impairment of growth. Evaluation of two brothers with dyskeratosis congenita, and review of previous reports, indicate the following to be more prominent in dyskeratosis congenita than in Fanconi’s anemia: cutaneous telangiectatic erythema and atrophy; exocrine, ungual, and dental dysplasias; mucosal leukoplakia, carcinomatosis, and stenosis; and esophageal diverticula. Prominent in Fanconi’s anemia but not dyskeratosis congenita are the renal and particular skeletal anomalies. Possible transition cases are discussed. The proband studied suffered from progressive refractory pancytopenia, fevers, abdominal pains, malabsorption syndrome, and finally subarachnoid hemorrhage. Cultured leukocytes had normal-appearing karyotypes. The proband’s brother had cutaneous alterations of dyskeratosis congenita, but a hemogram revealed only mild thrombocytopenia and macrocytosis. Both brothers had elevated levels of hemoglobin F, leukocyte alkaline phosphatase, serum IgG, and thyroglobulin antibody, and both had reduced levels of serum IgM and vitamin B12.


Blood ◽  
1970 ◽  
Vol 36 (6) ◽  
pp. 748-753 ◽  
Author(s):  
A. DAIBER ◽  
L. HERVEÉ ◽  
I. CON ◽  
A. DONOSO

Abstract Highly satisfactory results obtained with 50 mg./week nandrolone decanoate (Deca-Durabolin) for 3-16 months are reported in 10 cases of aplastic anemia. In the series thus treated there were only two deaths, occurring after only a few months of treatment. All other cases benefited to a large degree: in six, normalization was achieved, and a distinct improvement was seen in two still under treatment. Once therapy had been commenced, there was a period of latency which fluctuated between 1 and 9 months. Except for one patient with Fanconi’s anemia, the other normalized cases have not relapsed after suspension of the drug.


JAMA ◽  
1971 ◽  
Vol 216 (12) ◽  
pp. 2015 ◽  
Author(s):  
G. Arthur Van Voolen

2017 ◽  
Vol 9 (3) ◽  
Author(s):  
Cristina Olivieri ◽  
Anna Mondino ◽  
Matteo Chinello ◽  
Alessandra Risso ◽  
Enrico Finale ◽  
...  

Dyskeratosis congenita (DC) is an inherited bone marrow failure disorder characterized by mucocutaneous features (skin pigmentation, nail dystrophy and oral leukoplakia), pulmonary fibrosis, hematologic and solid malignancies. Its severe form, recognized as Hoyeraal-Hreidarsson syndrome (HHS), also includes cerebellar hypoplasia, microcephaly, developmental delay and prenatal growth retardation. In literature phenotypic variability among DC patients sharing the same mutation is wellknown. To our knowledge this report describes for the first time a family of DC patients, characterized by a member with features of classic DC and another one with some features of HHS, both with the same mutation in <em>DKC1</em>. Our family confirms again that one mutation can be associated with different phenotypes and different hematological manifestations. It’s possible to speculate that there are likely to be patients who do not clinically fit neatly into either classical DC or HHS, but whose clinical features are due to mutations in <em>DKC1</em> or in genes responsible for autosomal DC/HHS.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1608-1608
Author(s):  
Hiroki Yamaguchi ◽  
Hirotoshi Sakaguchi ◽  
Kenichi Yoshida ◽  
Miharu Yabe ◽  
Hiromasa Yabe ◽  
...  

Abstract Background: Dyskeratosis congenita (DKC) is an inherited bone marrow failure syndrome typified by reticulated skin pigmentation, nails dystrophy, and mucosal leukoplakia. Hoyeraal-Hreidarsson syndrome (HHS) is considered to be a severe form of DKC. Unconventional forms of DKC, which develop slowly in adulthood without physical anomalies characteristic to DKC, have been reported. Clinical and genetic features of DKC have been investigated in Caucasian, Black, and Hispanic populations, but never in Asian populations. Therefore, the present study aimed to determine the clinical and genetic features of DKC, HHS, and cryptic DKC among Japanese patients. Methods: We analyzed 16 patients diagnosed with DKC, 3 patients with HHS, and 21 patients with cryptic DKC between 2003 and 2014 in Japan. Telomere length was measured by Southern blot and/or flow-fluorescence in situ hybridization methods. Mutation analyses were performed using direct sequencing for DKC1, TERC, TERT, NOP10, NHP2, and TINF2. In some patients, we also analyzed the exon sequence and genome copy number using a next-generation sequencer. Results: Age at diagnosis was significantly older in the following order: HHS, DKC, and cryptic DKC (p<0.001). Twenty-five percent of DKC and HHS patients, and 33% of cryptic DKC patients, were women. Two DKC patients and six cryptic DKC patients had a family history. Characteristic findings of DKC included nail dystrophy (93.75%), reticulated skin pigmentation (87.5%), and lingual leukoplakia (81.3%), with 11/15 (68.8%) patients showing all three physical abnormalities. Characteristic findings of HHS were reticulated skin pigmentation 100%), nail dystrophy (66.7%), and lingual leukoplakia (33.3%); none of the patients had all three abnormalities. Regarding peripheral blood anomalies in DKC patients, peripheral blood count results at diagnosis revealed a marked reduction in platelet count among the three types of blood cells assessed: 7/16 (43.8%) patients had a platelet count ≤20000/µl, whereas only 1/16 (6.3%) patient had a neutrophil count ≤1000/µl or Hb ≤7g/dl. Telomere length analysis revealed that telomere length was shortened in 6/7 (85.7%) DKC patients, and all HHS and cryptic DKC patients. Mutations of telomere regulated genes were found in 11/16 (68.7%) DKC patients (DKC1 mutations in 5 patients, TINF2 mutations in 3 patients, TERT mutations in 2 patients, and TERC mutations in 1 patient). Among these, those harboring the homozygous TERT c.1002_1004del mutation showed a large deletion in the region encoding the TERT gene in one allele on chromosome number 5 by SNP array analysis. This is the first report of a large deletion in the TERT gene. With respect to HHS patients, no causative gene mutation could be identified for any of the patients. With respect to cryptic DKC patients, 11/21 (52.4%) patients had gene mutations (TERT mutations in 5 patients, TINF2 mutations in 3 patients, RTEL1 mutations in 2 patients (1 family), and TERC mutations in 1 patient). Those with RTEL1 mutations had mutations of both alleles, whereas those with the other mutations had heterozygous mutations. While the RTEL1 mutation is often discovered in HHS patients in the form of autosomal recessive inheritance, these two patients did not have apparent physical abnormalities characteristic to DKC, and thus represent the first case of cryptic DKC involving RTEL1 mutations. Immunosuppressive agents such as cyclosporine and steroids were administered to five patients, but no apparent efficacy was observed. Anabolic steroid hormones were also administered to five patients, and mild improvement in anemia was observed in one DKC patient, and mild improvement in reduced platelet count in one HHS patient. Hematopoietic stem cell transplantation was performed in eight patients, resulting in long-term survival in six of these patients (post-transplantation 10-year survival rate, 58.3%). Conclusions: The present study is the first to address DKC, HHS, and cryptic DKC in Japanese people, an Asian race. We found marked reductions in platelet counts in DKC patients in blood tests at diagnosis, a high prevalence of TINF2 mutations as the causative genetic mutation, and the existence of DKC patients with large deletions in the TERT gene and cryptic DKC patients with RTEL1 mutations on both alleles. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document